BRIEF published on 12/09/2025 at 18:35, 3 months 30 days ago Theraclion submits Sonovein to the FDA after significant progress FDA Theraclion SONOVEIN Varicose Veins HIFU
BRIEF published on 12/09/2025 at 18:35, 3 months 30 days ago Theraclion Submits Sonovein to FDA After Year of Key Achievements FDA Submission Clinical Evidence SONOVEIN Regulatory Achievements Varicose Vein Treatment
PRESS RELEASE published on 12/09/2025 at 18:30, 3 months 30 days ago Inside Information / Other news releases Theraclion announces FDA submission of Sonovein following a year of regulatory and clinical achievements. Key milestones in Europe and China also reached Clinical Milestones FDA Submission Theraclion SONOVEIN Regulatory Achievements
BRIEF published on 10/29/2025 at 18:35, 5 months 10 days ago Theraclion Announces 2025 Half-Year Financial Results and Strategic Progress Financial Results Revenue Growth Market Expansion U.S. Study Certification Progress
PRESS RELEASE published on 10/29/2025 at 18:30, 5 months 10 days ago Inside Information / News release on accounts, results Theraclion reports successful pivotal study, CE certification, GB 9706.1-2020 certification; 89% revenue increase and 23% operating loss reduction in 2025 half-year results Revenue Increase Operating Loss Reduction CE Certification Pivotal Study Theraclion
BRIEF published on 10/21/2025 at 18:35, 5 months 18 days ago Theraclion obtains crucial certification in China Medical Theraclion SONOVEIN® Focused Ultrasound Chinese Certification
BRIEF published on 10/10/2025 at 18:35, 5 months 29 days ago Monthly publication of Theraclion voting rights Share Capital Voting Rights Investment Euronext Growth Theraclion
PRESS RELEASE published on 10/10/2025 at 18:30, 5 months 29 days ago Inside Information / Other news releases Theraclion provides monthly update on total voting rights and shares. The French MedTech company uses focused ultrasound for non-invasive treatment. CE-marked platform SONOVEIN® targets varicose veins Voting Rights Shares Theraclion SONOVEIN Focused Ultrasound
BRIEF published on 09/15/2025 at 18:35, 6 months 23 days ago Theraclion Successfully Completes Pivotal Study with 96.8% Occlusion Rate FDA Clinical Trial Theraclion SONOVEIN® Varicose Veins
PRESS RELEASE published on 09/15/2025 at 18:30, 6 months 23 days ago Inside Information / Other news releases Theraclion announces successful U.S. FDA pivotal study showing 96.8% occlusion rate with Sonovein® for varicose vein treatment. Results support potential U.S. market entry Theraclion SONOVEIN® U.S. FDA Study Varicose Vein Treatment Occlusion Rate
Published on 04/09/2026 at 04:25, 1 hour 36 minutes ago Future Fuels Announces Completion of $2 Million Life Offering
Published on 04/09/2026 at 01:50, 4 hours 11 minutes ago CoTec Provides Update on Warrant Acceleration
Published on 04/08/2026 at 23:00, 7 hours 1 minute ago NXT Energy Solutions Announces SFD Survey Contract
Published on 04/08/2026 at 22:05, 7 hours 56 minutes ago GameSquare Achieves First Positive Adjusted EBITDA Quarter in Fourth Quarter, Marking Inflection to Operating Profitability
Published on 04/09/2026 at 04:15, 1 hour 46 minutes ago ESR Secures US$850 Million to Accelerate Long-term Growth
Published on 04/08/2026 at 23:54, 6 hours 7 minutes ago EQS-Adhoc: Raiffeisen Bank International AG: Raiffeisen Bank International AG announces its intention to launch a voluntary takeover offer to the shareholders of Addiko Bank AG
Published on 04/08/2026 at 23:30, 6 hours 31 minutes ago AMPERA Officially Opens World Headquarters in Florida
Published on 04/08/2026 at 23:21, 6 hours 39 minutes ago EQS-Adhoc: Raiffeisen Bank International AG: RBI announces intention to submit a voluntary public tender offer for all Addiko shares at EUR 23.05 per share
Published on 04/08/2026 at 21:03, 8 hours 57 minutes ago EQS-Adhoc: Elmos Semiconductor SE: Cancellation of 540,000 treasury shares (approx. 3.05% of the share capital)
Published on 04/08/2026 at 18:02, 11 hours 59 minutes ago Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 17:45, 12 hours 16 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 04/08/2026 at 12:58, 17 hours 2 minutes ago EURAZEO IS ASSIGNED A BBB CREDIT RATING (STABLE OUTLOOK) BY S&P AND A BBB CREDIT RATING (STABLE OUTLOOK) BY FITCH
Published on 04/08/2026 at 11:00, 19 hours 1 minute ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 04/08/2026 at 10:17, 19 hours 44 minutes ago BBB LONG-TERM CREDIT RATING WITH A STABLE OUTLOOK EXPECTED FOR EURAZEO FROM BOTH S&P AND FITCH
